Status:
COMPLETED
Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases
Lead Sponsor:
Fudan University
Conditions:
Colorectal Cancer Metastatic
Eligibility:
All Genders
18-75 years
Brief Summary
Chemotharapy plus targeted therapy regimen, as an adjuvant therapy, can effectively reduce the rate of both intrahepatic and extrahepatic recurrence in initially unresectable CRLM patients. Those with...
Detailed Description
This multi-center study enrolled consecutive patients with initially unresectable CRLM who underwent conversion therapy or radiofrequency ablation (RFA) and achieved no NED status between June 1, 2013...
Eligibility Criteria
Inclusion
- Age ≥ 18 and ≤ 75 years;
- Histologically confirmed CRC;
- Initially unresectable synchronous liver metastases (LMs);
- Accepted conversion therapy and successfully converted into resectable status;
- Underwent R0 intestinal and hepatic resection;
- Accepted adjuvant therapy.
Exclusion
- R1/R2 resection;
- Extrahepatic metastases;
- Accepted postoperative monotherapy;
- Lack of follow-up data.
Key Trial Info
Start Date :
January 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2023
Estimated Enrollment :
198 Patients enrolled
Trial Details
Trial ID
NCT06027775
Start Date
January 1 2013
End Date
January 1 2023
Last Update
September 7 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.